Eysuvis — CareFirst (Caremark)
Short-term treatment (up to two weeks) of the signs and symptoms of dry eye disease
Initial criteria
- The requested drug is being prescribed for the treatment of dry eye disease
- The request is for Eysuvis
- The requested drug is being prescribed for short-term use (up to two weeks)
Reauthorization criteria
- All patients (including new patients) requesting authorization for continuation of therapy for Eysuvis must meet all requirements in the coverage criteria section
Approval duration
3 months